US ▾
OMOMCL

Omnicell (OMCL) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Jul 30, 2026

Source: earnings call transcript

Executive summary

Omnicell Q2 FY26 — Strong Profitability Outperformance Amidst Sales Cycle Variability

Omnicell delivered strong Q2 FY26 financial results, particularly in profitability, driven by disciplined execution and a one-time tariff refund. While the company sees robust pipeline activity and increasing customer engagement for its new Titan XT and OmniSphere platforms, purchasing decisions are taking longer, leading to a wider full-year product bookings guidance range. Management remains confident in the long-term opportunity and its competitive positioning in the evolving healthcare technology landscape.

Highlights

5

  • Total revenue was $312 million, at the high end of the previously provided guidance range.

  • Non-GAAP EBITDA of $67 million was well above the previously shared outlook.

  • Non-GAAP earnings per share of $0.94 was well above the previously shared outlook.

  • Free cash flow for the quarter was $56 million, reflecting strong profitability.

  • Secured the first competitive Titan XT conversion win of the year with a health system in the Southeast.

Concerns

4

  • Full-year 2026 product bookings guidance revised to $425 million - $560 million, with the lower end reflecting uncertainty around timing of purchasing decisions.

  • Full-year 2026 ARR guidance revised to $660 million - $680 million due to anticipated longer development time for certain consumables growth opportunities.

  • Expected $6 million of incremental cost in H2 2026 from memory chip supply issues, impacting full-year consolidated gross margin by 50 basis points.

  • Q3 FY26 non-GAAP EBITDA guidance of $32 million - $37 million reflects the absence of a one-time tariff refund, lower expected revenue, lower gross margin, and higher operating expenses.

Guidance & targets

CategoryTargetConfidence
Q3 FY26 Total Revenue
$301 million to $307 million
high materiality
High
Q3 FY26 Product Revenue
$169 million to $172 million
medium materiality
High
Q3 FY26 Service Revenue
$132 million to $135 million
medium materiality
High
Q3 FY26 Non-GAAP EBITDA
$32 million to $37 million
high materiality
High
Q3 FY26 Non-GAAP EPS
$0.35 to $0.43
high materiality
High
Q3 FY26 Non-GAAP Effective Tax Rate
approximately 18%
low materiality
High
Full Year 2026 Product Bookings
$425 million to $560 million
high materiality
Medium
Full Year 2026 Total Revenue
$1.225 billion to $1.245 billion
high materiality
High
Full Year 2026 Product Revenue
$690 million to $700 million
medium materiality
High
Full Year 2026 Service Revenue
$535 million to $545 million
medium materiality
High
Full Year 2026 Year-end ARR
$660 million to $680 million
high materiality
Medium
Full Year 2026 Non-GAAP EBITDA
$175 million to $185 million
high materiality
High
Full Year 2026 Non-GAAP EPS
$2.15 to $2.30
high materiality
High

Product announcements

ProductTypeDetails
Titan XT Automated Dispensing Systemlaunch
OmniSphere-ADA Platformlaunch

Deals & partnerships

A health system in the Southeast First competitive Titan XT conversion win of the year.

Selected Titan XT alongside AWS, IV workflow, and other Omnicell solutions as part of a broader medication management transformation strategy. Flexible financing capabilities were an important differentiator.

World-class academic medical center in North Carolina, Texas-based academic health system, Arizona Regional Medical Center Existing customers selecting Titan XT automated dispensing system.

Selected Titan XT along with central pharmacy and inventory optimization solutions to support and modernize medication management operations.

Largest healthcare provider in Northwest Arizona Competitive greenfield win for Omnicell specialty pharmacy services.

Selected Omnicell specialty pharmacy services to enhance clinical outcomes and improve patient experience.

Health systems in Oregon and Missouri Opened two new specialty pharmacy engagements.

Expanding Omnicell's footprint in the fast-growing specialty pharmacy market.

Risks & headwinds

Variability in timing of purchasing decisions Remainder of 2026

Product bookings guidance range of $425 million to $560 million for FY26, with the bottom end reflecting timing uncertainty.

Mitigation:Strong pipeline activity, increased customer engagement, expanding leasing programs to offer flexible financing.

Imbalanced supply and demand for memory chips Second half of 2026

$6 million of incremental cost in H2 2026, representing roughly a 5x increase in costs versus the beginning of the year and a 50 basis point impact to full year consolidated gross margin and 80 basis points impact to full year product gross margin.

Mitigation:Strategic approach to inventory acquisition, including multi-sourcing initiatives and balancing near-term product demand with longer-term planning considerations; continued focus on disciplined cost management.

Longer development time for consumables growth opportunities FY26

Year-end 2026 ARR guidance revised to $660 million to $680 million.

Mitigation:Primarily timing related, not a change in customer demand or long-term confidence.

What to watch in Q3 FY26

Product bookings conversion

Next quarter (Q3 FY26 results)
Current FY26 guidance $425M-$560M
Target Progress towards upper end of guidance range, or narrowing of range

Why it matters

The wide range in product bookings guidance reflects uncertainty in the timing of large deals, which is critical for future revenue recognition.

The bottom end of this revised range primarily reflects uncertainty around the timing of purchasing decisions rather than the deterioration in demand for our solutions. The upper end of the guidance range remains unchanged from our prior guidance at $560 million, and reflects the transactions currently in our pipeline that we continue to believe may be completed in 2026.

Find out whether OMCL delivers this. Inve re-checks your case every morning.

Q&A highlights

Why was the bottom end of the FY26 product bookings guidance lowered significantly while the top end remained unchanged, creating a very wide range? Is the lower end due to cancellations or just timing, and what gives confidence in the unchanged upper end?

The top end remains unchanged because the company has line of sight to transactions that could achieve it. The lower end reflects variability in timing for medium-sized and large deals, making it hard to predict which will close by year-end, rather than a deterioration in demand. The pipeline is larger than in recent years.

“The bottom end of this revised range primarily reflects uncertainty around the timing of purchasing decisions rather than the deterioration in demand for our solutions. The upper end of the guidance range remains unchanged from our prior guidance at $560 million, and reflects the transactions currently in our pipeline that we continue to believe may be completed in 2026.”

asked by Allen Lutz · answered by H. Radford

2 min read 6 chapters

Detailed narrative

Organizational Update and Strategic Focus

Omnicell announced the promotion of Nnamdi Njoku to President and Chief Operating Officer, effective July 1. This move aims to accelerate execution, drive operational focus, and align the organization for scaling the business. Randall Lipps remains Chairman and CEO, and the company's strategy to become a market leader in autonomous medication management remains unchanged, reinforcing a commitment to disciplined execution and long-term value creation.

Evolving Market Dynamics and Customer Engagement

The company observes health systems prioritizing investments that enhance operational efficiency, strengthen reliability, and address staffing and cost pressures. Omnicell's solutions, particularly OmniSphere and Titan XT, are increasingly viewed as strategic enterprise-wide platforms, leading to increased pipeline activity. This involves broad cross-functional evaluations and longer planning cycles, creating competitive conversion opportunities.

Titan XT and OmniSphere Platform Momentum

Omnicell is in the early stages of a new refresh cycle with strong interest in its Titan XT automated dispensing system, reflected in a meaningful increase in pipeline activity. Titan XT is on track for shipment in H2 2026, and OmniSphere-ADA, the cloud-native platform unifying devices, data, and workflows, is on track for H1 2027 general availability. This cycle is unique as both Omnicell and its largest competitor have introduced new platforms concurrently, leading to more competitive deals and thorough customer evaluations.

Leasing Programs and Flexible Financing

To support customer investments and address the cost of change associated with broad enterprise deployments, Omnicell is expanding its leasing programs. Leveraging its balance sheet, these programs offer flexible financing options, which are proving to be an important differentiator in competitive situations. This approach helps support attractive lifetime value economics for both customers and Omnicell.

IV Product Line Update

Omnicell continues to work on its IVX program, aiming to meet internal benchmarks for broader availability. Management acknowledges that unlocking the IV market requires a suite of solutions, including semi- to fully-automatic options. While IVX development progresses, the company is also investing in its IV workflow product, which is seeing good demand, and building out its analytics platform to offer comprehensive solutions.

Memory Chip Supply and Cost Headwinds

The company is navigating an imbalanced supply and demand environment for memory chips, necessitating a strategic approach to inventory acquisition, including multi-sourcing. This dynamic is expected to result in $6 million of incremental costs in H2 2026, representing a 5x increase in costs compared to the beginning of the year and impacting full-year consolidated gross margin by 50 basis points.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.